Clarus Therapeutics Announces Issuance of Patent Covering JATENZO (Testosterone Undecanoate)
Clarus Therapeutics Holdings, Inc. recently announced that the United States Patent and Trademark Office (USPTO) has issued a new patent for claims that cover Clarus’ oral testosterone replacement product, JATENZO (testosterone undecanoate). Patent No. 11,331,325, titled Pharmaceutical Delivery Systems for Hydrophobic Drugs and Compositions Comprising Same, covers Clarus’ commercialized product, JATENZO. The new patent will expire in January 2027.
“This new patent further reinforces our already impressive intellectual property portfolio for JATENZO,” said Dr. Robert Dudley, President and Chief Executive Officer of Clarus. “We believe that having eight patents listed in FDA’s Orange Book underscores our multi-pronged strategy for success in the marketplace by protecting this important asset.”
Male hypogonadism is a condition that results when the testes do not produce enough testosterone. Symptoms associated with male hypogonadism can include depression, decreased sex drive, decreased muscle mass, and decreased bone density, among others. An estimated 20 million men in the United States have hypogonadism, with approximately six million patients diagnosed. Treatments for male hypogonadism may include testosterone replacement therapy.
Clarus Therapeutics Holdings, Inc. is a pharmaceutical company with expertise in developing androgen and metabolic therapies for men and women – including potential therapies for orphan indications. Clarus’ first commercial product is JATENZO (testosterone undecanoate). For more information, visit www.clarustherapeutics.com.
Total Page Views: 970
